GeneDx Holdings (WGSWW) Stock Analysis & Winston Score
GeneDx Holdings Corp. is a genomic testing company that analyzes DNA to help doctors diagnose rare diseases and genetic conditions. Its main customers are hospitals, clinicians, and families — especially those with sick children who need answers that regular tests cannot provide. The company is one of the largest providers of whole exome and whole genome sequencing in the United States. GeneDx makes money by charging for genetic tests, typically billed to insurance companies, hospitals, or patients directly. It operates primarily in the United States but processes samples from patients around the world. The company's competitive edge comes from its large database of genetic variants, which helps it interpret test results more accurately over time. However, GeneDx is not yet profitable, and its main risk is achieving the scale needed to turn its strong gross margins into positive operating income while navigating reimbursement challenges from insurers who may limit coverage for genomic testing.
Winston Score: 28/100 — Below Average
Below-average fundamentals — multiple weak pillars.
- Quality: Mixed (8/30)
- Growth: Mixed (7/20)
- Cash Flow: Weak (0/10)
- Stability: Mixed (4/10)
- Valuation: Data not available (0/10)
- Ownership: Good (8/15)
Key Facts
Price: $0.00
Market Cap: $1.8B
Sector: Healthcare
Industry: Medical - Healthcare Information Services
Exchange: NASDAQ Global Select
